0001209191-18-011403.txt : 20180220
0001209191-18-011403.hdr.sgml : 20180220
20180220170242
ACCESSION NUMBER: 0001209191-18-011403
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180215
FILED AS OF DATE: 20180220
DATE AS OF CHANGE: 20180220
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: KAPLAN GILLA
CENTRAL INDEX KEY: 0001247024
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-34912
FILM NUMBER: 18625544
MAIL ADDRESS:
STREET 1: C/O CELGENE CORPORATION
STREET 2: 86 MORRIS AVENUE
CITY: SUMMIT
STATE: NJ
ZIP: 07901
FORMER NAME:
FORMER CONFORMED NAME: KAPLAN GILLA PHD
DATE OF NAME CHANGE: 20030625
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CELGENE CORP /DE/
CENTRAL INDEX KEY: 0000816284
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 222711928
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 86 MORRIS AVENUE
CITY: SUMMIT
STATE: NJ
ZIP: 07901
BUSINESS PHONE: (908)673-9000
MAIL ADDRESS:
STREET 1: 86 MORRIS AVENUE
CITY: SUMMIT
STATE: NJ
ZIP: 07901
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-02-15
0
0000816284
CELGENE CORP /DE/
CELG
0001247024
KAPLAN GILLA
C/O CELGENE CORPORATION
86 MORRIS AVENUE
SUMMIT
NJ
07901
1
0
0
0
Common Stock
2018-02-15
4
M
0
9250
27.18
A
94801
D
Common Stock
2018-02-15
4
S
0
9250
95.989
D
85551
D
Common Stock
2018-02-20
4
S
0
9250
94.83
D
76301
D
Stock Option (right to buy)
27.18
2018-02-15
4
M
0
9250
0.00
D
2018-03-17
Common Stock
9250
0
D
The price reported in Column 4 is a weighted average price. These shares were sold by the reporting person in multiple transactions at prices ranging from $95.987 to $96.00, inclusive. The reporting person undertakes to provide to Celgene Corporation (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.
The option was fully exercisable.
The option was issued pursuant to the Company's 1995 Non-Employee Director's Incentive Plan.
/s/ Peter N. Kellogg, Attorney-in-Fact
2018-02-20